Why this matters now

The last few decades of biopharmaceutical research have seen an explosion in new therapies, many of which treat illnesses once thought impossible to manage. As innovation continues at an unprecedented pace, life sciences manufacturers are under increasing pressure to deliver new drugs and vaccines faster than ever without compromising safety and quality.

How are they accomplishing this goal? Digital technologies—more specifically, automation. As Nathan Pettus, an expert with decades of expertise in the life sciences industry, recently shared in an article in International Pharmaceutical Industry magazine,

“Automation, combined with smart data management, has emerged as the foundation for this transformation, enabling pharmaceutical and biotech companies to accelerate discovery through commercial production, boost manufacturing agility, safeguard product quality, deliver a reliable supply of high-quality products to market, and meet sustainability goals.”

That shift is already underway. With nearly 80% of biopharma leadership acknowledging the need to adopt digital technologies more aggressively, forward-thinking organizations are investing in capabilities such as advanced process control, DeltaV™ Manufacturing Execution System Electronic Batch Record Management, DeltaV Real Time Scheduling (RTS), simulation, and advanced analytics to improve speed to market without compromising safety or quality.

Takeaway: Automation is becoming foundational for delivering faster innovation without sacrificing safety or quality.

TL;DR

• Life sciences manufacturers face mounting pressure to accelerate drug development.
• Automation enables speed, agility, and consistency across the lifecycle.
• Integrated digital systems protect quality while improving throughput.
• Manufacturers are prioritizing automation aligned to industry-specific needs.
• A data-driven foundation supports scalability and long-term competitiveness.

Focused on priorities

To be as effective as possible, Nathan explains, organizations are focusing automation investments around five critical priorities for the life sciences industry.

Pipeline Acceleration

Gone are the days when paper-based, manual processes could support effective innovation. Manual data handling leads to errors, silos, and inefficient workflows.

Automation software such as DeltaV Process Knowledge Management accelerates technology transfer by simplifying scaling, iteration, and standardization—helping organizations bring treatments to patients faster while maximizing commercial potential.

Takeaway: Digital workflows accelerate innovation while reducing risk during technology transfer.

Flexible Manufacturing

As consumer needs shift toward personalized and smaller-batch therapies, manufacturing systems must adapt in real time.

Comprehensive automation solutions like the DeltaV for Life Sciences automation platform help translate processes, workflows, and recipes across products—minimizing downtime and risk in flexible production environments.

Takeaway: Flexible automation enables rapid product changeovers without compromising compliance.

Operational Integrity

Reducing variability is critical in life sciences manufacturing, where schedule certainty and quality compliance are non-negotiable.

Automation tools such as DeltaV RTS enforce processes that eliminate variation and maintain consistent manufacturing performance.

“One North American-based biopharmaceutical company that automated its planning process reduced time spent on maintenance by 95% compared to manual efforts. In addition, it ensured all critical equipment was available and ready to go when production plans called for it.”

Takeaway: Operational integrity improves dramatically when scheduling and execution are automated.

Real-Time Release

Product release depends on multiple coordinated steps—many of which benefit from automation and advanced analytics.

Capabilities such as continuous process verification, DeltaV Spectral Process Analytic Technology, electronic batch records, and real-time quality control help eliminate silos and support faster, safer product release.

Takeaway: Real-time release is enabled by integrated data, analytics, and automation.

Sustainable Operations

Life sciences manufacturers are also under growing pressure to operate more sustainably.

Automation improves visibility into energy, water, and material use while enabling more efficient processes such as closed-loop clean-in-place and steam-in-place.

Integrated predictive maintenance and control technologies also help prevent upsets that create excess waste.

Takeaway: Sustainable operations depend on automation-driven visibility and control.

Data is the key

These goals are achievable when automation systems are designed to integrate seamlessly and promote data mobility across the organization. Emerson’s enterprise operations platform establishes a seamless data fabric—from the intelligent field through the industrial edge and into the cloud—to empower decision-making and autonomy at scale.

It is never too early to begin building a holistic operations vision. In life sciences, an enterprise operations platform built on advanced automation provides a clear path to faster, safer, and more sustainable manufacturing.

Takeaway: Data mobility across the enterprise unlocks autonomy, speed, and operational excellence.